Amgen CEO says weight loss drug can address 'patient persistence issue'

Jan 14, 2026 - 12:00

Amgen CEO says weight loss drug can address 'patient persistence issue'

Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer.

Related Posts

Big Tech is poaching energy talent to fuel its AI ambitions

Big Tech is poaching energy talent to fuel its AI ambit...

Jan 14, 2026

At least 2,571 killed in Iran's protests, U.S.-based rights group HRANA says

At least 2,571 killed in Iran's protests, U.S.-based ri...

Jan 14, 2026

CNBC Daily Open: Worries over Iran and Fed independence weigh on markets

CNBC Daily Open: Worries over Iran and Fed independence...

Jan 14, 2026

Ford expands Bronco SUV performance lineup with 'more attainable' RTR model

Ford expands Bronco SUV performance lineup with 'more a...

Jan 14, 2026

Salesforce releases updated Slackbot powered by Anthropic's AI model

Salesforce releases updated Slackbot powered by Anthrop...

Jan 14, 2026

Delta CEO sees record earnings in reach again thanks to high-end travel demand

Delta CEO sees record earnings in reach again thanks to...

Jan 14, 2026